Premium
IC‐P‐040: EVALUATION OF TAU DEPOSITION IN AMYLOID POSITIVE MCI OR MILD‐AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [ 18 F]PI‐2620 PET
Author(s) -
Stephens Andrew Wills,
Bullich Santiago,
Mueller Andre,
Berndt Mathias,
Santi Susan,
Scott David,
Adamczuk Kate,
Suhy Joyce,
Kaplow June,
Krause Stephen,
Chang Julia,
Albala Bruce,
Luthman Johan
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4202
Subject(s) - dementia , psychology , cerebellar vermis , nuclear medicine , cortex (anatomy) , posterior parietal cortex , temporal cortex , medicine , pathology , cerebellum , neuroscience , disease
on brain atrophy and dysfunction. However, no information is yet available for the association between AC medication use and in vivo Alzheimer’s disease (AD) pathologies such as beta-amyloid deposition and AD-signature neurodegeneration. Therefore, we aimed to examine the association using multimodal neuroimaging in patients with mild cognitive impairment (MCI). Methods: This study included 134 MCI participants of the Korean Brain Aging Study for Early diagnosis and prediction of Alzheimer’s disease (KBASE). All participants underwent comprehensive clinical and neuropsychological assessment, C-Pittsburgh Compound B (PiB) positron emission tomography (PET), F-fluorodeoxyglucose (FDG) PET and brain magnetic resonance imaging. Exposure variable was the use of AC medications during 4 weeks before the assessment visit and participants were classified into AC+ or ACgroup. The list of AC medications was determined according to the literature review. Outcome variables were global PiB standardized uptake value ratio (SUVR), AD-signature region cerebral glucose metabolism (AD-CM), and hippocampal to intracranial volume ratio (HVR, %). Using the analysis of covariance, the mean values of outcome variables were compared between AC+ and ACgroup, after adjusting age, sex, apolipoprotein 34 positivity, clinical dementia rating scale sum of boxes score, total score of geriatric depression scale, and total number of prescribed medications and comorbidities. Results: Of the 134 participants, 55 (41.0 %) participants were taking ACmedications (Table 1). After adjusting potential covariates, the mean global PiB SUVR was higher in AC+ group than that of ACgroup, and both the mean AD-CM and mean HVR of the AC+ group were lower than those of ACgroup (Table 2). Conclusions: The findings suggest that AC medication use may contribute to in vivo AD pathologies, such as amyloid deposition and AD-type neurodegenerations, although further longitudinal studies are needed to confirm the relationship.